The 29-year-old daughter of Tim McGraw and Faith Hill revealed she now considers the popular weight-loss drug "probably one of the worst things" she ever did for herself, a cautionary note as millions of Americans chase the same shortcut. Gracie McGraw took to Instagram Stories on Monday to lay out, in blunt terms, what three […] The post Gracie McGraw says three years on Ozempic triggered her eating disorder relapse appeared first on American Almanac .
The 29-year-old daughter of Tim McGraw and Faith Hill revealed she now considers the popular weight-loss drug "probably one of the worst things" she ever did for herself, a cautionary note as millions of Americans chase the same shortcut. Gracie McGraw took to Instagram Stories on Monday to lay out, in blunt terms, what three years on Ozempic cost her. She started the drug in 2022 after being diagnosed with polyendocrine metabolic ovarian syndrome, a hormonal condition, previously called PCOS, that can cause irregular periods, weight gain, and long-term risks like type 2 diabetes. The drug did what it was supposed to do. It helped manage her symptoms. It made her lose weight. And it fed a disorder she thought she had left behind. As Page…Open
Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.
Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously,…Open
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.
